The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia

References

• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804–815.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Hillmen P. Clinical and diagnostic implications of monoclonal B-cell lymphocytosis. Best Pract Res Clin Haematol 2010;23:61–69.
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Efremov DG. Chronic lymphocytic leukemia: a tale of one or two signals?Cell Res 2013;23:182–185.
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219–234.
   PubMed Web of Science ®Google Scholar
• Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198–206.
   PubMed Web of Science ®Google Scholar
• Montserrat E, Sanchez-Bisono J, Vinolas N, et al. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986;62:567–575.
   PubMed Web of Science ®Google Scholar
• Gentile M, Cutrona G, Neri A, et al. Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages. Haematologica 2009;94:887–888.
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840–1847.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848–1854.
   PubMed Web of Science ®Google Scholar
• Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:1177–1184.
   PubMed Web of Science ®Google Scholar
• Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410–1416.
   PubMed Web of Science ®Google Scholar
• Krober A, Bloehdorn J, Hafner S, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006;24:969–975.
   PubMed Web of Science ®Google Scholar
• Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944–4951.
   PubMed Web of Science ®Google Scholar
• Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893–901.
   PubMed Web of Science ®Google Scholar
• Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363: 105–111.
   PubMed Web of Science ®Google Scholar
• Kipps TJ. The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007;20:415–424.
   PubMed Web of Science ®Google Scholar
• Seiler T, Dohner H, Stilgenbauer S. Risk stratification in chronic lymphocytic leukemia. Semin Oncol 2006;33:186–194.
   PubMed Web of Science ®Google Scholar
• Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008;22:211–219.
   PubMed Web of Science ®Google Scholar
• Wierda WG, O’Brien S, Wang X, et al. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 2009;27:1637–1643.
   PubMed Web of Science ®Google Scholar
• Damle RN, Temburni S, Calissano C, et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 2007;110:3352–3359.
   PubMed Web of Science ®Google Scholar
• Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia:association with progression and fludarabine-refractoriness. Blood 2011;118: 6904–6908.
   PubMed Web of Science ®Google Scholar
• Balatti V, Lerner S, Rizzotto L, et al. Trisomy 12 CLLs progress through NOTCH1 mutations. Leukemia 2013;27:740–743.
   PubMed Web of Science ®Google Scholar
• Oscier DG, Rose-Zerilli MJ, Winkelmann N, et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013;121:468–475.
   PubMed Web of Science ®Google Scholar
• Zenz T, Mertens D, Dohner H, et al. Importance of genetics in chronic lymphocytic leukemia. Blood Rev 2011;25:131–137.
   PubMed Web of Science ®Google Scholar
• Foà R, Del Giudice I, Guarini A, et al. Interphase fluorescence in situ hybridization analysis of del(11)(q23) and del(17)(p13) in chronic lymphocytic leukemia. A study of 40 early-onset patients. Cancer Genet Cytogenet 2003;140:31–36.
   PubMed Web of Science ®Google Scholar
• Gaidano G. Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica 2013;98:675–685.
   PubMed Web of Science ®Google Scholar
• Zenz T, Mertens D, Kuppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:37–50.
   PubMed Web of Science ®Google Scholar
• Zenz T, Frohling S, Mertens D, et al. Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol 2010;23:71–84.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910–1916.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Bullinger L, Lichter P, et al.; German CLL Study Group (GCLLSG). Chronic lymphocytic leukemia. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 2002;16:993–1007.
   PubMed Web of Science ®Google Scholar
• Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009;23:117–124.
   PubMed Web of Science ®Google Scholar
• Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009;15:995–1004.
   PubMed Web of Science ®Google Scholar
• Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia:results from a detailed genetic characterization with long-term follow-up. Blood 2008;112:3322–3329.
   PubMed Web of Science ®Google Scholar
• Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580–1589.
   PubMed Web of Science ®Google Scholar
• Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278–3281.
   PubMed Web of Science ®Google Scholar
• Thornton PD, Matutes E, Bosanquet AG, et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003;82:759–765.
   PubMed Web of Science ®Google Scholar
• Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006;20:1441–1445.
   PubMed Web of Science ®Google Scholar
• Gribben JG. How I treat CLL up front. Blood 2009;115:187–197.
   PubMed Web of Science ®Google Scholar
• Fegan C, Robinson H, Thompson P, et al. Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia 1995;9:2003–2008.
   PubMed Web of Science ®Google Scholar
• Neilson JR, Auer R, White D, et al. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia 1997;11:1929–1932.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997; 89:2516–2522.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Liebisch P, James MR, et al. Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders. Proc Natl Acad Sci USA 1996;93:11837–11841.
   PubMed Web of Science ®Google Scholar
• Gunn SR, Hibbard MK, Ismail SH, et al. Atypical 11q deletions identified by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia. Leukemia 2009;23:1011–1017.
   PubMed Web of Science ®Google Scholar
• Gunnarsson R, Mansouri L, Isaksson A, et al. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica 2011;96:1161–1169.
   PubMed Web of Science ®Google Scholar
• Gardiner A, Parker H, Glide S, et al. A new minimal deleted region at 11q22.3 reveals the importance of interpretation of diminished FISH signals and the choice of probe for ATM deletion screening in chronic lymphocytic leukemia. Leuk Res 2012;36:307–310.
   PubMed Web of Science ®Google Scholar
• Wierda WG, O’Brien S, Wang X, et al. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol 2011;29:4088–4095.
   PubMed Web of Science ®Google Scholar
• Marasca R, Maffei R, Martinelli S, et al. Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia:prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. Hematol Oncol 2013;31:348–355.
   Web of Science ®Google Scholar
• Roos G, Kröber A, Grabowski P, et al. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood 2008;111:2246–2252.
   PubMed Web of Science ®Google Scholar
• Ouillette P, Collins R, Shakhan S, et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood 2011;118:3051–3061.
   PubMed Web of Science ®Google Scholar
• Ouillette P, Fossum S, Parkin B, et al. Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. Clin Cancer Res 2010;16:4135–4147.
   PubMed Web of Science ®Google Scholar
• Kujawski L, Ouillette P, Erba H, et al. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood 2008;112:1993–2003.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006;24:4634–4641.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Sander S, Bullinger L, et al. Clonal evolution in chronic lymphocytic leukemia:acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007;92:1242–1245.
   PubMed Web of Science ®Google Scholar
• Britt-Compton B, Lin TT, Ahmed G, et al. Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage. Leukemia 2012;26:826–830.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230–239.
   PubMed Web of Science ®Google Scholar
• Dickinson JD, Smith LM, Sanger WG, et al. Unique gene expression and clinical characteristics are associated with the 11q23 deletion in chronic lymphocytic leukaemia. Br J Haematol 2005;128:460–471.
   PubMed Web of Science ®Google Scholar
• Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007;25:799–804.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616–5623.
   PubMed Web of Science ®Google Scholar
• Oscier D, Wade R, Davis Z, et al. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 2010;95:1705–1712.
   PubMed Web of Science ®Google Scholar
• Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473–4479.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006;24:437–443.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia:a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:3994–4001.
   PubMed Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wang X, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011;117: 3016–3024.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Tam C, Abruzzo LV, et al. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 2009;115:373–380.
   PubMed Web of Science ®Google Scholar
• Lozanski G, Ruppert AS, Heerema NA, et al. Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. Leuk Lymphoma 2012;53:1743–1748.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291–5297.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399–404.
   PubMed Web of Science ®Google Scholar
• Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012;119:2854–2862.
   PubMed Web of Science ®Google Scholar
• Lavin MF, Scott S, Gueven N, et al. Functional consequences of sequence alterations in the ATM gene. DNA Repair (Amst) 2004;3: 1197–1205.
   Google Scholar
• Taylor AM, Metcalfe JA, Thick J, et al. Leukemia and lymphoma in ataxia telangiectasia. Blood 1996;87:423–438.
   PubMed Web of Science ®Google Scholar
• Bosotti R, Isacchi A, Sonnhammer EL. FAT: a novel domain in PIK-related kinases. Trends Biochem Sci 2000;25:225–227.
   PubMed Web of Science ®Google Scholar
• Sun Y, Xu Y, Roy K, et al. DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity. Mol Cell Biol 2007;27:8502–850.
   PubMed Web of Science ®Google Scholar
• Beamish H, Kedar P, Kaneko H, et al. Functional link between BLM defective in Bloom's syndrome and the ataxia-telangiectasia-mutated protein, ATM. J Biol Chem 2002;277:30515–30523.
   PubMed Web of Science ®Google Scholar
• Fernandes N, Sun Y, Chen S, et al. DNA damage-induced association of ATM with its target proteins requires a protein interaction domain in the N terminus of ATM. J Biol Chem 2005;280:15158–15164.
   PubMedGoogle Scholar
• Falck J, Coates J, Jackson SP. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005;434: 605–611.
   PubMed Web of Science ®Google Scholar
• Young DB, Jonnalagadda J, Gatei M, et al. Identification of domains of ataxia-telangiectasia mutated required for nuclear localization and chromatin association. J Biol Chem 2005;280:27587–27594.
   PubMed Web of Science ®Google Scholar
• Seidel JJ, Anderson CM, Blackburn EH. A novel Tel1/ATM N-terminal motif, TAN, is essential for telomere length maintenance and a DNA damage response. Mol Cell Biol 2008;28:5736–5746.
   PubMed Web of Science ®Google Scholar
• Chen S, Paul P, Price BD. ATM's leucine-rich domain and adjacent sequences are essential for ATM to regulate the DNA damage response. Oncogene 2003;22:6332–6339.
   PubMed Web of Science ®Google Scholar
• Llorca O, Rivera-Calzada A, Grantham J, et al. Electron microscopy and 3D reconstructions reveal that human ATM kinase uses an arm-like domain to clamp around double-stranded DNA. Oncogene 2003;22:3867–3874.
   PubMed Web of Science ®Google Scholar
• Paull TT, Lee JH. The Mre11/Rad50/Nbs1 complex and its role as a DNA double-strand break sensor for ATM. Cell Cycle 2005;4:737–740.
   PubMed Web of Science ®Google Scholar
• Lee JH, Paull TT. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 2005;308:551–554.
   PubMed Web of Science ®Google Scholar
• Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003;421:499–506.
   PubMed Web of Science ®Google Scholar
• Kozlov SV, Graham ME, Jakob B, et al. Autophosphorylation and ATM activation: additional sites add to the complexity. J Biol Chem 2011;286:9107–9119.
   PubMed Web of Science ®Google Scholar
• Sun Y, Xu Y, Roy K, et al. DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity. Mol Cell Biol 2007;27:8502–8509.
   PubMed Web of Science ®Google Scholar
• Goodarzi AA, Jonnalagadda JC, Douglas P, et al. Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. EMBO J 2004;23:4451–4461.
   PubMed Web of Science ®Google Scholar
• Goodarzi AA, Noon AT, Deckbar D, et al. ATM signaling facilitates repair of DNA double-strand breaks associated with heterochromatin. Mol Cell 2008;31:167–177.
   PubMed Web of Science ®Google Scholar
• Pilch DR, Sedelnikova OA, Redon C, et al. Characteristics of gamma-H2AX foci at DNA double-strand breaks sites. Biochem Cell Biol 2003;81:123–129.
   PubMed Web of Science ®Google Scholar
• Kinner A, Wu W, Staudt C, et al. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 2008;36:5678–5694.
   PubMed Web of Science ®Google Scholar
• Barlow C, Liyanage M, Moens PB, et al. Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways. Nat Genet 1997;17:453–456.
   PubMed Web of Science ®Google Scholar
• Matsuoka S, Rotman G, Ogawa A, et al. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 2000;97:10389–10394.
   PubMed Web of Science ®Google Scholar
• Banin S, Moyal L, Shieh S, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998;281:1674–1677.
   PubMed Web of Science ®Google Scholar
• Falck J, Petrini JH, Williams BR, et al. The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways. Nat Genet 2002;30:290–294.
   PubMed Web of Science ®Google Scholar
• Yazdi PT, Wang Y, Zhao S, et al. SMC1 is a downstream effector in the ATM/NBS1 branch of the human S-phase checkpoint. Genes Dev 2002;16:571–582.
   PubMed Web of Science ®Google Scholar
• Buscemi G, Savio C, Zannini L, et al. Chk2 activation dependence on Nbs1 after DNA damage. Mol Cell Biol 2001;21:5214–5222.
   PubMed Web of Science ®Google Scholar
• Gary PH, Margossian HS, Taniguchi T, et al. Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Mol Cell Biol 2006;26:7005–7015.
   PubMed Web of Science ®Google Scholar
• Xu B, O’Donnell AH, Kim ST, et al. Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Cancer Res 2002; 62:4588–4591.
   PubMed Web of Science ®Google Scholar
• Hopfner KP, Karcher A, Craig L, et al. Structural biochemistry and interaction architecture of the DNA double-strand break repair Mre11 nuclease and Rad50-ATPase. Cell 2001;105:473–485.
   PubMed Web of Science ®Google Scholar
• Williams RS, Moncalian G, Williams JS, et al. Mre11 dimers coordinate DNA end bridging and nuclease processing in double-strand-break repair. Cell 2008;135:97–109.
   PubMed Web of Science ®Google Scholar
• Riballo E, Kuhne M, Rief N, et al. A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Mol Cell 2004;16:715–724.
   PubMed Web of Science ®Google Scholar
• Chen L, Morio T, Minegishi Y, et al. Ataxia-telangiectasia-mutated dependent phosphorylation of Artemis in response to DNA damage. Cancer Sci 2005;96:134–141.
   PubMed Web of Science ®Google Scholar
• Beamish H, Kedar P, Kaneko H, et al. Functional link between BLM defective in Bloom's syndrome and the ataxia-telangiectasia-mutated protein, ATM. J Biol Chem 2002;277:30515–30523.
   PubMed Web of Science ®Google Scholar
• Shafman T, Khanna KK, Kedar P, et al. Interaction between ATM protein and c-Abl in response to DNA damage. Nature 1997;387:520–523.
   PubMed Web of Science ®Google Scholar
• Chen G, Yuan SS, Liu W, et al. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J Biol Chem 1999;274:12748–12752.
   PubMed Web of Science ®Google Scholar
• Zhang J, Willers, Feng Z, et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 2004;24:708–718.
   PubMed Web of Science ®Google Scholar
• Stewart GS, Last JI, Stankovic T, et al. Residual ataxia telangiectasia mutated protein function in cells from ataxia telangiectasia patients, with 5762ins137 and 7271T> G mutations, showing a less severe phenotype. J Biol Chem 2001;276:30133–30141.
   PubMed Web of Science ®Google Scholar
• Mailand N, Bekker-Jensen S, Faustrup H, et al. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 2007;131:887–900.
   PubMed Web of Science ®Google Scholar
• You Z, Shi LZ, Zhu Q, et al. CtIP links DNA double-strand break sensing to resection. Mol Cell 2009;36:954–969.
   PubMed Web of Science ®Google Scholar
• Bree RT, Neary C, Samali A, et al. The switch from survival responses to apoptosis after chromosomal breaks. DNA Repair (Amst) 2004;3:989–995.
   PubMed Web of Science ®Google Scholar
• Bai L, Zhu WG. p53: structure, function and therapeutic applications. J Cancer Mol 2006;2:141–153.
   Google Scholar
• Wang JY. Regulation of cell death by the Abl tyrosine kinase. Oncogene 2000;19:5643–5650.
   PubMedGoogle Scholar
• Yoshida K, Ozaki T, Furuya K, et al. ATM-dependent nuclear accumulation of IKK-alpha plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin. Oncogene 2008;27:1183–1188.
   PubMed Web of Science ®Google Scholar
• Carcagno AL, Ogara MF, Sonzogni SV, et al. E2F1 transcription is induced by genotoxic stress through ATM/ATR activation. IUBMB Life 2009;61:537–543.
   PubMedGoogle Scholar
• Guo Z, Kozlov S, Lavin MF, et al. ATM activation by oxidative stress. Science 2010;330:517–521.
   PubMed Web of Science ®Google Scholar
• Thanasoula M, Escandell JM, Suwaki N, et al. ATM/ATR checkpoint activation downregulates CDC25C to prevent mitotic entry with uncapped telomeres. EMBO J 2012;31:3398–3410.
   PubMed Web of Science ®Google Scholar
• Bredemeyer AL, Sharma GG, Huang CY, et al. ATM stabilizes DNA double-strand-break complexes during V(D)J recombination. Nature 2006;442:466–470.
   PubMed Web of Science ®Google Scholar
• Reina-San-Martin B, Chen HT, Nussenzweig A, et al. ATM is required for efficient recombination between immunoglobulin switch regions. J Exp Med 2004;200:1103–1110.
   PubMed Web of Science ®Google Scholar
• Pan-Hammarström Q, Lähdesmäki A, Zhao Y, et al. Disparate roles of ATR and ATM in immunoglobulin class switch recombination and somatic hypermutation. J Exp Med 2006;203:99–110.
   PubMed Web of Science ®Google Scholar
• Bullrich F, Rasio D, Kitada S, et al. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res 1999;59:24–27.
   PubMed Web of Science ®Google Scholar
• Stankovic T, Weber P, Stewart G, et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999;353:26–29.
   PubMed Web of Science ®Google Scholar
• Stankovic T, Stewart GS, Fegan C, et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood 2002;99:300–309.
   PubMed Web of Science ®Google Scholar
• Austen B, Powell JE, Alvi A, et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005;106:3175–3182.
   PubMed Web of Science ®Google Scholar
• Skowronska A, Austen B, Powell JE, et al. ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele. Haematologica 2012;97:142–146.
   PubMed Web of Science ®Google Scholar
• Schaffner C, Stilgenbauer S, Rappold GA, et al. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999;94:748–753.
   PubMed Web of Science ®Google Scholar
• Swift M, Reitnauer PJ, Morrell D, et al. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987;316:1289–1294.
   PubMed Web of Science ®Google Scholar
• Bevan S, Catovsky D, Marossy A, et al. Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia. Leukemia 1999;13:1497–1500.
   PubMed Web of Science ®Google Scholar
• Yuille MR, Condie A, Hudson CD, et al. ATM mutations are rare in familial chronic lymphocytic leukemia. Blood 2002;100:603–609.
   PubMed Web of Science ®Google Scholar
• Rudd MF, Sellick GS, Webb EL, et al. Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia. Blood 2006;108:638–644.
   PubMed Web of Science ®Google Scholar
• Enjuanes A, Benavente Y, Bosch F, et al. Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res 2008;68:10178–10186.
   PubMed Web of Science ®Google Scholar
• Austen B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007;25:5448–5457.
   PubMed Web of Science ®Google Scholar
• Cuneo A, Bigoni R, Rigolin GM, et al. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance. Haematologica 2002;87:44–51.
   PubMed Web of Science ®Google Scholar
• Pettitt AR, Sherrington PD, Stewart G, et al. p53 dysfunction in B-cell chronic lymphocytic leukemia:inactivation of ATM as an alternative to TP53 mutation. Blood 2001;98:814–822.
   PubMed Web of Science ®Google Scholar
• Stankovic T, Hubank M, Cronin D, et al. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. Blood 2004;103:291–300.
   PubMed Web of Science ®Google Scholar
• Skowronska A, Parker A, Ahmed G, et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J Clin Oncol 2012;30:4524–4532.
   PubMed Web of Science ®Google Scholar
• Guarini A, Marinelli M, Tavolaro S, et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica 2012;97:47–55.
   PubMed Web of Science ®Google Scholar
• Malek SN. The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia. Oncogene 2013;32:2805–2817.
   PubMed Web of Science ®Google Scholar
• Schuh A, Becq J, Humphray S, et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood 2012;120: 4191–4196.
   PubMed Web of Science ®Google Scholar
• Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365: 2497–2506.
   PubMed Web of Science ®Google Scholar
• Carter A, Lin K, Sherrington PD, et al. Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia. Br J Haematol 2004;127:425–428.
   PubMed Web of Science ®Google Scholar
• Carter A, Lin K, Sherrington PD, et al. Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia. Leukemia 2006;20:737–740.
   PubMed Web of Science ®Google Scholar
• Mohr J, Helfrich H, Fuge M, et al. DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. Blood 2011;117:1622–1632.
   PubMed Web of Science ®Google Scholar
• Lin K, Adamson J, Johnson GG, et al. Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration. Clin Cancer Res 2012;18:4191–4200.
   PubMed Web of Science ®Google Scholar
• Te Raa GD, Malcikova J, Pospisilova S, et al.; European Research Initiative on CLL (ERIC). Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia. Leuk Lymphoma 2013;54: 1849–1853.
   PubMed Web of Science ®Google Scholar
• Best OG, Gardiner AC, Majid A, et al. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia 2008;22:1456–1459.
   PubMed Web of Science ®Google Scholar
• Navrkalova V, Sebejova L, Zemanova J, et al. ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia:Application of functional test using doxorubicin. Haematologica 2013;98:1124–1131.
   PubMed Web of Science ®Google Scholar
• Johnson GG, Sherrington PD, Carter A, et al. A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene. Cancer Res 2009;69:5210–5217.
   PubMed Web of Science ®Google Scholar
• Ouillette P, Li J, Shaknovich R, Li Y, et al. Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. Genes Chromosomes Cancer 2012;51:1125–1132.
   PubMed Web of Science ®Google Scholar
• Weston VJ, Oldreive CE, Skowronska A, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 2010;116:4578–4587.
   PubMed Web of Science ®Google Scholar
• Martín M, Terradas M, Tusell L, et al. ATM and DNA-PKcs make a complementary couple in DNA double strand break repair. Mutat Res 2012 Jan 2. [Epub ahead of print]
   Web of Science ®Google Scholar
• Reaper PM, Griffiths MR, Long JM, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 2011;7:428–430.
   PubMed Web of Science ®Google Scholar
• Kennedy RD, Chen CC, Stuckert P, et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 2007;117:1440–1449.
   PubMed Web of Science ®Google Scholar